Don’t Jump to SGLT2 Inhibitors for Patients WithOUT Diabetes
December 2020
You’ll hear buzz about using SGLT2 inhibitors (Jardiance, etc) in patients withOUT diabetes...for heart failure or kidney disease.
That’s because growing evidence suggests these meds may improve outcomes when added to standard therapy.
In heart failure with reduced ejection fraction (HFrEF), adding Jardiance (empagliflozin) over 16 months prevents hospitalization or CV death in about 1 in 14 type 2s...or 1 in 26 patients withOUT diabetes.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: MD includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote